

118TH CONGRESS
1ST SESSION

H. R. 6674

To provide for the periodic issuance of up-to-date clinical guidance on addressing the health effects of per- and polyfluoroalkyl substances (PFAS), and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

DECEMBER 7, 2023

Mr. KILDEE (for himself and Mr. LAWLER) introduced the following bill;
which was referred to the Committee on Energy and Commerce

A BILL

To provide for the periodic issuance of up-to-date clinical guidance on addressing the health effects of per- and polyfluoroalkyl substances (PFAS), and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Better Care for PFAS
5 Patients Act of 2023”.

1 **SEC. 2. PFAS HEALTH EFFECTS ASSESSMENT, REC-**
2 **COMMENDATIONS, AND GUIDANCE.**

3 (a) PERIODIC ASSESSMENT AND RECOMMENDA-
4 TIONS.—

5 (1) AGREEMENT.—The Director of the Agency
6 for Toxic Substances and Disease Registry (in this
7 section referred to as the “Director”) shall enter
8 into an agreement with the National Academies of
9 Sciences, Engineering, and Medicine (or another ap-
10 propriate entity if the National Academies declines
11 to enter into such agreement) under which the Na-
12 tional Academies or the other appropriate entity
13 agrees—

14 (A) to assess the health effects of per- and
15 polyfluoroalkyl substances (in this section re-
16 ferred to as “PFAS”) that can be measured in
17 human tissues;

18 (B) to formulate clinical recommendations
19 on addressing such health effects;

20 (C) not later than 2 years after the date
21 of entry into such agreement, to complete the
22 initial assessment under subparagraph (A) and
23 formulate the initial recommendations under
24 subparagraph (B); and

25 (D) to update the most recent assessment
26 and recommendations under this paragraph—

- 1 (i) every 5 years; or
2 (ii) more frequently as determined
3 necessary by the Director based on an as-
4 sessment of the science.

5 (2) TIMING OF ENTRY INTO AGREEMENT.—The
6 Director shall enter into the agreement required by
7 paragraph (1) not later than 60 days after the date
8 of enactment of this Act.

9 (b) UP-TO-DATE GUIDANCE.—Based on the results
10 of the most recent assessment and recommendations
11 under subsection (a), the Director, in consultation with
12 the entity with which the Director enters into the agree-
13 ment under subsection (a), shall—

14 (1) not later than 5 years after the date of
15 entry into the agreement required by subsection
16 (a)—

17 (A) issue up-to-date clinical guidance on
18 addressing the health effects of PFAS;

19 (B) post such guidance on the public
20 website of the Agency for Toxic Substances and
21 Disease Registry; and

22 (C) disseminate such guidance to State
23 and local public health authorities and appro-
24 priate health care professionals; and

1 (2) every 5 years thereafter, or more frequently
2 as determined necessary by the Director based on an
3 assessment of the science, issue, post, and dissemi-
4 nate up-to-date guidance as described in paragraph
5 (1).

○